Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randal W Berg

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Toxicology and Applied Pharmacology|November 3, 2004
Toxicology of antisense therapeuticsTracey L H Jason, James Koropatnick, Randal W Berg
Cancer Gene Therapy|April 8, 2003
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistanceRandal W Berg, Peter J Ferguson, Mark D Vincent, et al.
Gene Expression|July 4, 2007
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugsTracey L H Jason, Randal W Berg, Mark D Vincent, et al.
Current Drug Targets|July 10, 2002
The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messengerRandal W Berg, Peter J Ferguso, Janice M DeMoor, et al.
DNA and Cell Biology|March 25, 2008
ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell linesTracey L H Jason, Rene Figueredo, Peter J Ferguson, et al.
Molecular Cancer Therapeutics|July 5, 2006
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesotheliomaJanet Flynn, Randal W Berg, Tracy Wong, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Toxicology and Applied Pharmacology|November 3, 2004
Toxicology of antisense therapeuticsTracey L H Jason, James Koropatnick, Randal W Berg
Cancer Gene Therapy|April 8, 2003
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistanceRandal W Berg, Peter J Ferguson, Mark D Vincent, et al.
Gene Expression|July 4, 2007
Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugsTracey L H Jason, Randal W Berg, Mark D Vincent, et al.
Current Drug Targets|July 10, 2002
The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messengerRandal W Berg, Peter J Ferguso, Janice M DeMoor, et al.
DNA and Cell Biology|March 25, 2008
ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell linesTracey L H Jason, Rene Figueredo, Peter J Ferguson, et al.
Molecular Cancer Therapeutics|July 5, 2006
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesotheliomaJanet Flynn, Randal W Berg, Tracy Wong, et al.
Pageof 1